Leading Chinese humanoid robot maker UBTech gets US$1 billion boost from Infini Capital


UBTech Robotics, a leading Chinese manufacturer of factory robots, has secured a credit line of up to US$1 billion from a Hong Kong investment firm to finance its production expansion, including a joint venture in the Middle East.

The Hong Kong-listed company said in an exchange filing on Sunday it would receive funding from Infini Capital, an investment conglomerate headquartered in Hong Kong and Abu Dhabi. The support would come through share allocations, convertible bonds and expedited loans.

The deal comes as Chinese private investors raise their bets on domestic humanoid robotics companies, which are actively expanding into international markets. Infini Capital, for example, is known for its investments in hi-tech companies, including artificial intelligence firms Beijing Fourth Paradigm Technology and SenseTime.

Infini Capital opened its Abu Dhabi office in March 2024. Founder and CEO Tony Chin said at the time that the firm intended to capitalise on the “deepening investments between Greater China and the Middle East”.

01:18

China unveils world’s first humanoid robot that can change its own batteries

China unveils world’s first humanoid robot that can change its own batteries

The firm plans to help UBTech establish a research centre and a “super factory” in the Middle East. It also aims to increase its holdings in UBTech to a 5 per cent equity stake, leveraging its previous investments in the AI and robotics supply chains to help the Shenzhen-based robot manufacturer develop “more powerful and cost-effective humanoid robots”.

  • Related Posts

    JD.com posts first quarterly loss in nearly four years as delivery battle takes toll

    Chinese e-commerce giant JD.com reported a 2.7 billion yuan (US$392 million) loss in the fourth quarter and a halving of annual profit amid an ongoing food delivery battle it ignited…

    Continue reading
    China and Hong Kong should relax biotech listing rules, venture capitalist says

    Mainland China and Hong Kong should ease listing rules for biotechnology companies and lower takeover thresholds for listed firms to capitalise on renewed foreign interest in the healthcare sector, venture…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *